Drug intelligence / Profile preview

Longqing

Development stage: Unknown
Lead developer: Department of Urology
Administration: Oral

Overview

Longqing is a Traditional Chinese Medicine (TCM) formulation, typically administered as Longqing tablets (Longqing Pian), used for the treatment and prevention of urinary tract infections (UTIs). It is an approved Chinese patent medicine (Zhongchengyao) based on the traditional Ba Zheng San formula, which is intended to clear heat, detoxify, and promote diuresis. The drug is indicated for acute uncomplicated lower UTIs and is currently being evaluated in clinical trials for the prevention of UTIs in patients with indwelling ureteral stents following lithotripsy for renal and ureteral calculi. These clinical studies are primarily led by the Department of Urology at Tongji Hospital, Huazhong University of Science and Technology.

Brand names: Longqing
Other names: Longqing tabletsLongqing Pian

Beyond the preview

Go deeper on Longqing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longqing.

Explore the full profile